Founded in 2015, Implant B is a start- up company engaged in the field of dental implantology.
The Company is developing a novel multi-piece dental implant, which enables the replacement of the implant’s surface in the case of Peri-implantitis (PI) development, while maintaining the original implant spatial position and dental restoration.
Located in Nazareth, Israel, the company secured financing of 3M NIS from NGT3 VC (www.ngt3vc.com) and the Israeli Office of Chief Scientist (OCS).
Peri Implantitis is a destructive inflammatory process affecting the soft and hard tissues surrounding dental implants, causing significant loss of supporting bone. Between 28 and 56% of dental implantees and 12 to 43% of dental implants are effected by this pathology.
The current treatment protocols for PI include different techniques for implant surface treatments or decontamination. None of these methods provide a definitive solution, i.e. renewal of bone to implant integration.
Untreated PI can lead to dental implant removal and replacement. Dental implant loss requires a lengthy healing process and the introduction of new, one or more, implants. Consequently, an expensive, time-consuming restoration replacement process follows the dental implant replacement.
The global dental implant market is estimated to be $7 Billion and expected to grow up to 10.4$ Billion by 2020.
The Implant-B Solution
Implant-B’s renewable implant is composed of two modules:
an implant body, which resembles regular implant (1) and a thin titanium sleeve (2).
The implant and the sleeve are pre-assembled during manufacturing in a configuration identical to regular implant thus assuring the insertion of the implant is similar to standard procedure.
Once PI develops, the restoration is removed, the contaminated sleeve is extracted and replaced by a new, uncontaminated sleeve, providing a new surface with no PI related residuals. The restoration is then returned to its original position.
Implant B’s solution is the only one providing both:
- Re-oseointegration after Peri Implantitis
- Maintenance of the original dental implant and prosthetic restoration
Zohar Gendler- Chairman of the BOD
Former CEO and director of Beta-O2 Technologies. Served as CEO of the Technion Entrepreneurial Incubator for a period of 11 years. Zohar led the establishment and investment in more than 50 companies.
Dr. Arie Ben Josef, DMD, Msc – Director
Over 20 years of managerial experience in the medical device and healthcare industries. Former CEO of ETView Medical, he took public in 2010 and led to 3 consecutive public offerings.
Dr. Ben Josef is a graduate of the Hebrew University and Haddasah Dental School of Medicine.
Dr. Liat Chaushu, DMD, Msc- Founder & Director
Graduate of Tel Aviv University’s dental school. MSc in Clinical Periodontics Main expertise include prosthodontics, periodontics, aesthetic and restorative dentistry.
Maria Ziv- R&D manager
Former project manager at MIS, the 5th largest dental implant manufacturer in the world. BSc in biomedical engineering (Ben-Gurion University)
Scientific Advisory Board
Prof. Gabi Chausho, DMD, Msc
Director of Oral & Maxillofacial Surgery department Rabin Medical Center (Petah Tikva, Israel). Associate Professor, Dept. of Oral & Maxillofacial Surgery, Tel Aviv University. Former Chair of the Israeli Association of Oral & Maxillofacial Surgery.
Prof. Haim Tal, DMD, M.dent., PhD.
Chairman of the Department of Periodontology and Implantology, Tel-Aviv University.
Former Dean of the Tel Aviv University School of Dental Medicine (1991-1996 ; 2006-2010).
PCT application filed on March 2015
Regulatory approvals are expected to be:
- FDA 510 (k) clearance
- CE Mark: Class II (b)